Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2007
02/08/2007WO2007014711A1 17-alpha-substituted derivatives of estradiol with wound-healing activity
02/08/2007WO2007014707A1 Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
02/08/2007WO2007014687A1 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
02/08/2007WO2007014652A1 TREATMENT OF TUMOURS WITH IKK-ß INHIBITORS
02/08/2007WO2007014619A1 Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
02/08/2007WO2007014608A1 Quadratic acid ii derivatives
02/08/2007WO2007014586A1 Use of megestrol acetate for the treatment of obstructive pulmonary diseases
02/08/2007WO2007014524A1 Erianin salts, their preparation methods and pharmaceutical compositions containing the same
02/08/2007WO2007014515A1 Use of hydroxybenzoic acid ester and analogues for the manufacture of a mendicament for the prevention and treatment of virus infection
02/08/2007WO2007014514A1 Use of p-hydroxybenzoic acid and analogues for the manufacture of a mendicament for the prevention and treatment of skin mucosa virus infection
02/08/2007WO2007014498A1 Analgesic huperzine and the derivatives thereof
02/08/2007WO2007014491A1 Acyclic nucleotide phosphonates and their use in antiviral agents
02/08/2007WO2007014476A1 Pharmaceutical composition containing indometacin and/or acemetacin
02/08/2007WO2007014469A1 Hepatitis c antivirals
02/08/2007WO2007014462A1 Ep4 receptor agonist, compositions and methods thereof
02/08/2007WO2007014454A1 Ep4 receptor agonist, compositions and methods thereof
02/08/2007WO2007014450A1 Use of voacamine and related compounds in the treatment of malaria
02/08/2007WO2007014409A1 Pleuromutilin derivatives useful as antibacterials
02/08/2007WO2006135796A3 Crystalline forms of a pyrrolotriazine compound
02/08/2007WO2006129318A3 Benzofuran derivatives with therapeutic activities
02/08/2007WO2006129257A3 Ketolide derivatives as antibacterial agents
02/08/2007WO2006129168A3 Bicyclic derivatives for the treatment of abnormal cell growth
02/08/2007WO2006129161A3 Vitamin formulation
02/08/2007WO2006128471A3 A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
02/08/2007WO2006127899A3 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
02/08/2007WO2006127898A3 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
02/08/2007WO2006126171A3 New antibiotic derivatives
02/08/2007WO2006124904A3 Cancer treatment by combined inhibition of telomerase and hsp90 activities
02/08/2007WO2006124573A3 Treatment of cancer with 2-deoxyglucose
02/08/2007WO2006123249A3 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
02/08/2007WO2006123229A3 Novel heterocyclic derivatives
02/08/2007WO2006121856A3 Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
02/08/2007WO2006117762A3 Antimicrobial agents
02/08/2007WO2006116309A3 Polymorphic and amorphous salt forms of squalamine dilactate
02/08/2007WO2006113704A3 Subtituted heteroaryl cb1 antagonists
02/08/2007WO2006110477A3 Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
02/08/2007WO2006109175A3 Solid dosage form of an antidiabetic drug
02/08/2007WO2006106220B1 Topical compositions comprising several mono- and/or oligosaccharides for treating skin diseases of warm blood hair coated animals.
02/08/2007WO2006104945A3 Hepatitis c therapies
02/08/2007WO2006101244A3 Method and composition for treating mucosal disorders
02/08/2007WO2006100026A8 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
02/08/2007WO2006099864A3 Pellet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo
02/08/2007WO2006096439A3 Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
02/08/2007WO2006091841A3 Compositions and their uses directed to il-4r alpha
02/08/2007WO2006091702A3 Multimediator dopamine transport inhibitors, and uses related thereto
02/08/2007WO2006091529A3 A solid pharmaceutical dosage formulation
02/08/2007WO2006088875A3 Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
02/08/2007WO2006087759A3 Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
02/08/2007WO2006086775A3 Methods and compositions for reducing systemic toxicity of vectors
02/08/2007WO2006081152A3 Estrogen receptor modulators
02/08/2007WO2006078422A3 Methods for modulating tumor growth and metastasis
02/08/2007WO2006077494A3 A process for preparing solid dosage forms for extended-release of biguanide and sulfonylurea
02/08/2007WO2006074204A3 Topical stabilized prostaglandin e compound dosage forms
02/08/2007WO2006071775A3 Novel compounds useful for bradykinin b1 receptor antagonism
02/08/2007WO2006064228A3 Thiazolopyramidine compounds for the modulation of chemokine receptor activity
02/08/2007WO2006063152A3 Immunostimulatory combinations and methods
02/08/2007WO2006063010A3 Compounds and methods of use thereof
02/08/2007WO2006062980A3 Stable non-crystalline formulation comprising tiagabine
02/08/2007WO2006062732A3 Compounds acting at the centrosome
02/08/2007WO2006055526B1 Compositions useful to treat ocular neovascular diseases and macular degeneration
02/08/2007WO2006052810A3 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
02/08/2007WO2006052718A8 Farnesyltransferase inhibitors for treating sepsis
02/08/2007WO2006050301A3 Dye-free pharmaceutical suspensions and related methods
02/08/2007WO2006048633A3 Combination comprising zd6474 and an antiandrogen
02/08/2007WO2006045119A3 Improved inhibitors for the soluble epoxide hydrolase
02/08/2007WO2006031756A3 Betulinol derivatives as anti-cancer agents
02/08/2007WO2006015944A3 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
02/08/2007WO2006015943A3 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
02/08/2007WO2005113006A3 Use of dipyridamole for treatment of resistance to platelet inhibitors
02/08/2007WO2005110490A8 Phospholipase c gamma modulation and uses thereof for management of pain and nociception
02/08/2007WO2005107728A3 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
02/08/2007WO2005103054A3 Bridged piperazine and piperidine derivatives as ccri antagonists
02/08/2007WO2005094329A3 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
02/08/2007WO2005092021A3 Ethanol extraction of phytosterols from corn fiber
02/08/2007WO2005091891A8 Compositions and methods for preventing and treating skin and hair conditions
02/08/2007WO2005084315A3 Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
02/08/2007WO2005075385A3 Method for producing dry powders of one or several carotenoids
02/08/2007WO2005070460A3 Combination therapy with 5-ht1a and 5-ht1b receptor antagonists
02/08/2007WO2005011613A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
02/08/2007WO2005006881A3 Salt taste modification
02/08/2007WO2003059267A3 SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
02/08/2007US20070032668 Semi-synthesis of taxane intermediates from a mixture of taxanes
02/08/2007US20070032666 intermediate for side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones); 4-Bromo-5(bromomethylene)-3-(1-bromoethyl)-2(5H)-furanone from N-bromosuccinimide the 3-ethylfuranone
02/08/2007US20070032664 Making intermediates such as ((4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-ethyl}-2-phenyl-[1,3]dioxan-4-yl)-acetic acid methyl ester for the synthesis of calcium atorvastatin (Lipitor(reg))
02/08/2007US20070032663 Intermediate in the synthesis of calcium atorvastatin (Lipitor(reg)) comprising an amine salt of a carboxylic acid, for example 2-(morpholinocarbonyl)ethylamine, phenylacetic acid salt
02/08/2007US20070032662 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrole-3-carboxylic acid and phenylamide
02/08/2007US20070032653 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc.
02/08/2007US20070032642 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
02/08/2007US20070032640 Cytokine receptor
02/08/2007US20070032558 Method of treating herpes viral infections using a halogenated hydrocarbon composition
02/08/2007US20070032557 Method for administering levosimendan
02/08/2007US20070032556 Aromatic polyamine derivative
02/08/2007US20070032555 Novel aryloxyphenyl-propanamines
02/08/2007US20070032554 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
02/08/2007US20070032553 Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
02/08/2007US20070032552 Crystalline maleic acid and 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol; analgesic
02/08/2007US20070032551 Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof
02/08/2007US20070032550 Novel salts and methods for their preparation
02/08/2007US20070032549 Process for obtaining HMG-CoA reductase inhibitors of high purity
02/08/2007US20070032548 Administering a polyunsaturated fatty acid of docosahexaenoic acid, docosapentaenoic acid, and/or arachidonic acid